שולי רווח נקי ממכירות: DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Corp - לוגו גרפי של המנפיק DMAC

The net margin ratio for DiaMedica Therapeutics (DMAC) on GURU.Markets reflects the company's pricing power in implementing blood flow restoration therapy, where the value 0.00 represents the latest figure. The brand is valued for the safety of its molecules in treating kidney failure and strokes. However, business sustainability relies on the patents for the drug DM199, the success of which depends directly on the results of ongoing clinical trials.

רווחיות מכירות לפי רווח נקי DiaMedica Corp (DMAC): לתקופה 04.07.2022 - 20.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור DiaMedica Pharma (DMAC)

ניתוח כל מדדי החברה:DiaMedica Therapeutics Inc - DMAC
סחורת הדגל של DiaMedica Therapeutics Inc

For DiaMedica Therapeutics (DMAC), whose model relies on R&D without current sales, the final sales margin indicator on GURU.Markets demonstrates the efficiency of operating expense management relative to available income. This metric is calculated as the ratio of net income to revenue, reflecting the business's ability to generate free cash flow and protect capital from cost inflation prior to the commercialization of the drug.